1. de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII – Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–74.
2. D’Amico G, Bernardi M, Angeli P. Towards a new definition of decompensated cirrhosis. J Hepatol. 2022;76(1):202–7.
3. Biggins SW, Angeli P, Garcia‐Tsao G, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the
American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-1048
4. Kulkarni A, Kumar P, Singh S, et al. Prevention of Paracentesis Induced Circulatory Dysfunction‐ A Systematic Review and Network Meta‐Analysis. J Clin Transl Hepatol. 2020;8(1):42-48
5. Angeli P, Bernardi M, Villanueva C, et al. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–60.
6. Angeli P, Wong F, Watson H, Ginès P. Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology. 2006;44:1535–42.
7. Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. Gut. 2021;70(1):9.
8. Wang S, Zhang X, Han T, et al. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia. BMC Gastroenterol. 2018;18(1):137.
9. Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites Gut.
2015;64(4):531-7.
10. Huelin P, Piano S, Solà E, et al. Validation of a Staging System for Acute Kidney Injury in Patients With Cirrhosis and Association With Acute-on-Chronic Liver Failure. Clinical Gastroente-
rology and Hepatology. 2017;15(3):438-445.e5.
11. Wang H, Liu F. Clinical characteristics of hepatopulmonary syndrome and hepatorenal syndrome and associated therapeutic potential of transjugular intrahepatic portosystemic shunt. iLI-
VER 2023;2(1):67–72
12. Florence W, Chris PS, P CM, et al. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. New England Journal of Medicine. 2021;384(9):818–28.
13. Koulaouzidis A, Bhat S, Karagiannidis A, Tan W, Linaker B. Spontaneous bacterial peritonitis. Postgrad Med J. 2007;83:379–83.
14. Oey R, Buuren H, de Jong D, Erler N, Man R. Bacterascites: A study of clinical features, microbiological findings, and clinical significance. Liver International. 2018;38.
15. Dever JB, Sheikh MY. Review article: spontaneous bacterial peritonitis – bacteriology, diagnosis, treatment, risk factors and prevention. Aliment Pharmacol Ther. 2015;41(11):1116–31
16. Runyon BA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology.
2013;57(4):1651–3.
17. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the
American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014–48.
18. Fernández J, Bert F, Nicolas-Chanoine MH. The challenges of multi-drug-resistance in hepatology. J Hepatol. 2016;65(5):1043–54.
19. Montagnese S, Russo FP, Amodio P, et al. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Dig Liver Dis. 2019;51(2):190–
205.
20. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. J Hepatol. 2022;77(3):807-824
21. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European
Association for the Study of the Liver. Hepatology. 2014;60(2).
22. Butterworth R, McPhail M. l-Ornithine l-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses. Drugs. 2019;79(Suppl
1):31-37.
23. Maharshi S, Sharma B. Prophylaxis of hepatic encephalopathy: current and future drug targets. Hepatol Int. 2024 Mar 16. doi: 10.1007/s12072-024-10647-9. Online ahead of print.
24. González-González JA, García-Compean D, Vázquez-Elizondo G, Garza-Galindo A, Jáquez-Quintana JO, Maldonado-Garza H. Nonvariceal upper gastrointestinal bleeding in patients with
liver cirrhosis. Clinical features, outcomes and predictors of in-hospital mortality. A prospective study. Ann Hepatol. 2011;10(3):287–95.
25. Pallio S, Melita G, Shahini E, et al. Diagnosis and Management of Esophagogastric Varices. Diagnostics. 2023;13(6):1031.
26. Kaplan DE, Ripoll C, Thiele M, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology. 2024;79(5):1180-1211.
27. Zia HA, Aby ES, Rabiee A. An Update on the Management of Esophageal Variceal Hemorrhage. Clin Liver Dis Clin Liver Dis. 2021; 18(4): 179–183.
28. Diaz-Soto MP, Garcia-Tsao G. Management of varices and variceal hemorrhage in liver cirrhosis: a recent update. Therap Adv Gastroenterol. 2022;15:1-12.
29. Wells M, Chande N, Adams P, et al. Meta-analysis: vasoactive medications for the management of acute variceal bleeds. Aliment Pharmacol Ther. 2012;35(11):1267–78.
30. Kim H, Lee Y, Yim H, et al. Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome. Clin Mol Hepatol. 2013;19:417–20.
31. Müller M, Seufferlein T, Perkhofer L, Wagner M, Kleger A. Self-Expandable Metal Stents for Persisting Esophageal Variceal Bleeding after Band Ligation or Injection-Therapy: A Retrospective
Study. PLoS One. 201510(6):e0126525-.
32. Masood I, Moshksar A, Wong B, Khan H, Saleem A. A comprehensive review of transvenous obliteration techniques in the management of gastric varices. Diagn Interv Radiol. 2023 Jan
31;29(1):146-154.
33. Pfisterer N, Unger L, Reiberger T. Clinical algorithms for the prevention of variceal bleeding and rebleeding in patients with liver cirrhosis. World J Hepatol. 2021;13:731–46.
34. Bhat Y, Weilert F, Fredrick R, et al. EUS-guided treatment of gastric fundal varices with combined injection of coils and cyanoacrylate glue: A large U.S. experience over 6 years (with video).
Gastrointest Endosc. 2016;83(6):1164-72.
35. Haq I, Tripathi D. Recent advances in the management of variceal bleeding. Gastroenterol Rep (Oxf). 2017; 5(2): 113–126.
36. Garcia‐Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Associ-
ation for the study of liver diseases. Hepatology. 2017;65(1):310-7
37. Francoz C, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol. 2012;57(1):203–12
38. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol. 2016;64(1):179–202.
39. Northup PG, Garcia‐Pagan JC, Garcia‐Tsao G, et al. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the
American Association for the Study of Liver Diseases. Hepatology. 2021;73(1):366-413.
40. Francoz C, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol. 2012;57(1):203–12
41. Ayuso C, Rimola J, Vilana R, et al. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol. 2018;101:72–81.
42. De Muzio F, Grassi F, Dell’Aversana F, et al. A Narrative Review on LI-RADS Algorithm in Liver Tumors: Prospects and Pitfalls. Diagnostics (Basel). 2022;12(7):1655.
43. Zaccherini G, Weiss E, Moreau R. Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment. JHEP Reports. 2020;3:100176.
44. Luo J, Li J, Li P, et al. Acute-on-chronic liver failure: far to go—a review. Crit Care. 2023;27(1):259.